2023 World Conference on Lung Cancer (Posters)-EP02.01. Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

EP02.01. Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases - PDF(Abstract)

Back to course

Pdf Summary

This study explored the use of silibinin, a substance that inhibits the STAT3 signaling pathway, for the treatment of non-small cell lung cancer (NSCLC) brain metastases. The researchers conducted a retrospective study of NSCLC patients with brain metastases in the province of Girona, Spain. They collected data on patient characteristics, treatment, and outcomes. They also analyzed the impact of silibinin use on patient survival.<br /><br />The results showed that among the 2,830 NSCLC patients, 457 developed brain metastases. The median overall survival for NSCLC patients with brain metastases was 4.44 months for adenocarcinoma, 2.17 months for squamous cell carcinoma, and 2.34 months for not otherwise specified (NOS). Among the 211 patients who received brain radiotherapy and systemic treatment, 57 also received silibinin. The analysis showed that patients who received silibinin had a significantly longer overall survival than those who did not (10.6 months vs. 6.30 months).<br /><br />A multivariate analysis identified silibinin treatment as a statistically significant independent variable for improved survival. Other factors that were associated with survival included histology, targeted mutations, the presence of extra-brain disease, Eastern Cooperative Oncology Group (ECOG) performance status, corticosteroid use, and brain surgery.<br /><br />The researchers concluded that silibinin supplementation may be beneficial for the management of NSCLC brain metastases. They suggested that prospective clinical trials should be conducted to further evaluate the efficacy of silibinin and other STAT3 inhibitors for this indication. Overall, these findings provide insights into potential molecular therapeutic targets for the treatment of NSCLC brain metastases.

Asset Subtitle

Joaquim Bosch-Barrera

Meta Tag

Speaker Joaquim Bosch-Barrera

Topic Tumor Biology: Preclinical Biology - Molecular Therapeutic Targets

Keywords

silibinin

STAT3 signaling pathway

NSCLC

brain metastases

retrospective study

overall survival

adenocarcinoma

squamous cell carcinoma

brain radiotherapy

molecular therapeutic targets